<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993600</url>
  </required_header>
  <id_info>
    <org_study_id>2018/09OCT/374</org_study_id>
    <nct_id>NCT03993600</nct_id>
  </id_info>
  <brief_title>New Markers of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Sweat</brief_title>
  <official_title>MucoSWEATomics New Markers of CFTR Function in Sweat: Value for Diagnosis and Efficacy of Target Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Liège</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to identify new biomarkers of CFTR function in sweat and in sweat
      gland.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sweat is a watery solution containing trace amounts of proteins and peptides that may
      contribute to the antimicrobial defense system of the skin barrier, playing a role in innate
      immune responses against potential pathogens. The peptide and metabolite composition of sweat
      has not been fully explored. Evidence suggests that the composition of the skin barrier could
      vary with diseases. The causes and consequences of the changes of sweat proteins and peptides
      in humans are unknown. This clinical trial will focus on multiomics analysis of sweat, mainly
      of the antimicrobial peptides that play a key role in the host-pathogen interaction.
      Antioxidants, anti-bacterial and anti-inflammatory compounds may contribute to the regulation
      of systemic inflammation and pathophysiological disorders. In cystic fibrosis, inflammatory
      responses are altered, exaggerated and persistent, even in the absence of infection. It is
      therefore relevant to study the influence of CFTR mutations on the profile of antimicrobial
      peptides expressed in sweat. The clinical study will potentially lead to the discovery of
      novel non-invasive biomarkers of the disease in sweat.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three groups will be done : healthy volunteer, cystic fibrosis patient and heterozygotes subject</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Descriptive statistical analysis</measure>
    <time_frame>one day</time_frame>
    <description>The assessment of the quantity of sweat secreted will be measured in mg with a scale, the sweat chloride concentration will be done by coulometric titration and expressed in mmol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proteomics, peptidomics and metabolomics analysis on sweat and sweat glands</measure>
    <time_frame>2 years</time_frame>
    <description>The quantity of total protein will be analysed with a colorimetric assay and will be expressed in mg/ml.
The identification of the different protein will be performed with different software, databases and algorithms such as Proteome Discoverer (version 1.4.1.14), Mascot software (version 2.2.0.6), MaxQuant (version 1.5.2.8), Andromeda, Uniprot, LFQ and Perseus (version 1.5.0.15).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Biomarkers</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sweat test and skin biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Cystic fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sweat test and skin biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygotes subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sweat test and skin biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)</intervention_name>
    <description>three groups:
Healthy volunteers
Patients with Cystic fibrosis
Heterozygous subjects</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Heterozygotes subjects</arm_group_label>
    <arm_group_label>Patients with Cystic fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject aged of 18 years or more.

          -  The patients with cystic fibrosis must have a confirmed diagnosis, be clinically
             stable, have a Forced Expiratory Volume in one second (FEV1) ≥ 30 and an O2 saturation
             ≥ 92%. F508del homozygous will been tested.

          -  Heterozygosity (parents of patients) will be confirmed by the presence of a single
             F508del mutation.

        Exclusion Criteria:

          -  Presence of an acute infection

          -  Pregnancy and lactation

          -  Subjects currently included in another clinical trial

          -  Subjects with forearm skin alterations

          -  Subjects with signs of dehydration

          -  Smokers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresinha Leal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresinha Leal, MD, PhD</last_name>
    <phone>00 32 2 764 9473</phone>
    <phone_ext>49473</phone_ext>
    <email>teresinha.leal@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey Reynaerts</last_name>
    <phone>00 32 2 764 9472</phone>
    <phone_ext>49472</phone_ext>
    <email>audrey.reynaerts@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>cliniques universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Reynaerts</last_name>
      <phone>003327649472</phone>
      <phone_ext>49472</phone_ext>
      <email>audrey.reynaerts@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Teresinha Leal, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Mazzucchelli, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>sweat</keyword>
  <keyword>sweat glands</keyword>
  <keyword>omics analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

